Expertise in
5
conditions

Ann-lii L. Cheng

No.57, Ln. 155, Sec. 3, Keelung Rd, 106, 
Da'an, TPQ, TW 
Expertise in
5
conditions
No.57, Ln. 155, Sec. 3, Keelung Rd, 106, 
Da'an, TPQ, TW 

Overview

Ann-lii Cheng practices practicing medicine in Da'an, Taiwan.

Cheng is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Liver Cancer, B-Cell Lymphoma, Non-Hodgkin Lymphoma, Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

They are actively involved in clinical research, co-authoring 351 peer reviewed articles and participating in 4 clinical trials.

Locations

No.57, Ln. 155, Sec. 3, Keelung Rd, 106, Da'an, TPQ, Taiwan
Other Locations
7 Chung Shan South Road, TPQ, Taiwan
7 Chung Shan S Rd, TPQ 10002, Taiwan
No. 7, Chung Shan South Rd, TPQ 10002, Taiwan
Hsin Chu Branch, Hsinchu, TNQ, Taiwan
No. 7 Chung Shan South Road, TPQ 10002, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Phase: Not Applicable
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma
An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: February 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

351 Total Publications

Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B-cell lymphoma.
Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B-cell lymphoma.
Journal: The journal of pathology. Clinical research
Published: April 11, 2026

Frequently Asked Questions about Ann-lii L. Cheng

Is Ann-lii L. Cheng a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Ann-lii L. Cheng is classified as an Distinguished expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ann-lii L. Cheng participate in research or clinical trials?

Yes. Ann-lii L. Cheng has published 351 articles and abstracts on conditions like Liver Cancer. You can view a list of Ann-lii L. Cheng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cheng's expertise for a condition
ConditionClose
    View All 35 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile